Intersect ENT (XENT): NDR Highlights Many Possible Drivers And Low Valuation - Piper Jaffray

August 25, 2016 7:21 AM EDT
Get Alerts XENT Hot Sheet
Price: $16.60 +0.61%

Rating Summary:
    10 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade XENT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, Matt O'Brien, reiterated his Overweight rating on shares of Intersect ENT (NASDAQ: XENT) after hosting management meetings. The analyst believes that the recent negative issues (sales force disruption and reimbursement) are not hurting the business much at this point. There are several growth drivers available, which collectively should yield low 20% growth on the top line over the next several years. Profitability is not imminent but XENT has plenty of cash, and likely will not need another round of financing. With a reasonable revenue multiple (3.4x ’17E sales) and an even more attractive EV/GP multiple (currently at a 37% discount to its peers) to go along with a compelling growth outlook and pipeline of products, the name should be owned at these levels.

No change to the price target of $21.

For an analyst ratings summary and ratings history on Intersect ENT click here. For more ratings news on Intersect ENT click here.

Shares of Intersect ENT closed at $15.51 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

Piper Jaffray

Add Your Comment